Publication
The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.
Authors not recorded
Cancer Res2014PMID 25056119PMC4167745stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerMelanomacivic_curation1.00
- drugDabrafenibcivic_curation1.00
- drugVemurafenibcivic_curation1.00
- geneRAC1civic_curation1.00
- variantRAC1 P29Scivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25056119
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| RAC1 P29S1 | ||||||||
| Dabrafenib + VemurafenibSubstitutes | Melanoma | Predictive | D | Supports Resistance | 4 | accepted | EID873Melanoma cell lines harboring the RAC1 P29S hotspot mutation were shown to be resistant to BRAF inhibition with vemurafenib or dabrafenib and knock-in or knock-out of this mutation decreased and incre… (full text at CIViC) PMID 25056119 · Watson et al., 2014 · Open in CIViC | civic |